Delaware
|
000-51481
|
13-3986004
|
(State or Other
|
(Commission File
|
(I.R.S. Employer
|
Jurisdiction of
|
Number)
|
Identification No.)
|
Incorporation)
|
|
|
|
5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
|
19044
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date: October 19, 2020
|
By:
|
/s/ Matthew C. Hill
|
|
|
|
Matthew C. Hill
|
|
|
Chief Financial Officer
|
|
•
|
An initial regimen for up to 12 weeks of office-based targeted excimer laser therapy is considered medically necessary for the treatment of
localized vitiligo after failure, intolerance or contraindications of trials with a topical corticosteroid and calcineurin inhibitor.
|
•
|
Continued office-based targeted excimer laser therapy beyond the initial 12 weeks and for up to 52 weeks is considered medically necessary for
the treatment of localized or generalized vitiligo when there is a beneficial clinical response to treatment.
|
•
|
Continued office-based targeted excimer laser therapy beyond the initial 52 weeks and for up to and including 200 total treatments is
considered medically necessary for the treatment of localized or generalized vitiligo when there is continued beneficial clinical response.
|
•
|
Previously, Cigna did not cover excimer laser therapy for the treatment of localized or generalized vitiligo because such treatment was
considered cosmetic and not medically necessary.
|
Matthew Hill, Chief Financial Officer
|
||
STRATA Skin Sciences, Inc.
|
||
215-619-3200
|
||
ir@strataskin.com
|